Maternus-Kliniken Aktiengesellschaft

XTRA:MAK Stock Report

Market Cap: €33.6m

Maternus-Kliniken Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Maternus-Kliniken.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth27.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) 25% Share Price Plunge Could Signal Some Risk

Aug 21
Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) 25% Share Price Plunge Could Signal Some Risk

Maternus-Kliniken Aktiengesellschaft (ETR:MAK) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 05
Maternus-Kliniken Aktiengesellschaft (ETR:MAK) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

A Piece Of The Puzzle Missing From Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) Share Price

Mar 13
A Piece Of The Puzzle Missing From Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) Share Price

Maternus-Kliniken (ETR:MAK) Will Be Hoping To Turn Its Returns On Capital Around

Jul 27
Maternus-Kliniken (ETR:MAK) Will Be Hoping To Turn Its Returns On Capital Around

The Returns On Capital At Maternus-Kliniken (ETR:MAK) Don't Inspire Confidence

Feb 22
The Returns On Capital At Maternus-Kliniken (ETR:MAK) Don't Inspire Confidence

Some Investors May Be Worried About Maternus-Kliniken's (ETR:MAK) Returns On Capital

Jul 27
Some Investors May Be Worried About Maternus-Kliniken's (ETR:MAK) Returns On Capital

Estimating The Fair Value Of Maternus-Kliniken Aktiengesellschaft (ETR:MAK)

Jun 10
Estimating The Fair Value Of Maternus-Kliniken Aktiengesellschaft (ETR:MAK)

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maternus-Kliniken has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

XTRA:MAK - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024109-71319N/A
3/31/2024106-11611N/A
12/31/2023102-14-13N/A
9/30/2023102-17-21N/A
6/30/2023102-19-20N/A
3/31/2023105-1602N/A
12/31/2022107-1424N/A
9/30/2022108-1057N/A
6/30/2022110-6811N/A
3/31/2022111-41214N/A
12/31/2021111-31517N/A
9/30/2021114-51819N/A
6/30/2021116-72021N/A
3/31/2021115-81617N/A
12/31/2020114-101112N/A
9/30/2020116-1099N/A
6/30/2020117-1067N/A
3/31/2020121-101011N/A
12/31/2019124-101516N/A
9/30/2019125-71213N/A
6/30/2019125-51011N/A
3/31/2019125-388N/A
12/31/2018124-256N/A
9/30/2018125-289N/A
6/30/2018126-21112N/A
3/31/2018126-2N/A11N/A
12/31/2017127-1N/A10N/A
9/30/20171270N/A7N/A
6/30/20171262N/A5N/A
3/31/20171251N/A6N/A
12/31/20161241N/A8N/A
9/30/20161244N/A4N/A
6/30/20161242N/A6N/A
3/31/20161242N/A-1N/A
12/31/20151232N/A-3N/A
9/30/201512328N/A2N/A
6/30/201512428N/A2N/A
3/31/201512328N/A8N/A
12/31/201412227N/A11N/A
9/30/2014120-9N/A12N/A
6/30/2014118-10N/A10N/A
3/31/2014115-11N/A11N/A
12/31/2013114-13N/A7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MAK's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if MAK's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if MAK's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if MAK's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if MAK's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MAK's Return on Equity is forecast to be high in 3 years time


Discover growth companies